Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162

National Cholesterol Education Program

Lenfant, C. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400060019005 · Cited by 1,188

Hypertriglyceridemia as a cardiovascular risk factor

Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

(1994) · Circulation · doi:10.1161/01.cir.89.3.1333 · Cited by 817

Epidemiology as a Guide to Clinical Decisions: The Association between Triglyceride and Coronary Heart Disease

Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702

Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality

Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657

Management of Dyslipidemia in NIDDM

Garg, A., & Grundy, S. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.2.153 · Cited by 260

Fibrinogen and coronary heart disease--what does it mean?

Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998) · PubMed · Cited by 256

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961

Obesity, Metabolic Syndrome, and Cardiovascular Disease

Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0372 · Cited by 1,395

The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence

WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 465

Diagnosis and management of the metabolic syndrome

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 437

LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 429

Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy

Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395

Association Among Rheumatoid Arthritis, Oral Hygiene, and Periodontitis

Pischon, N., Pischon, T., Kröger, J.-C., Gülmez, E., Kleber, B. M., Bernimoulin, J. ‐., Landau, H., Brinkmann, P. ‐., Schlattmann, P., Zernicke, J., et al. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.070501 · Cited by 387

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

Stein, E. A., Dufour, R., Gagné, C., Gaudet, D., East, C. A., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. P. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 297

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

Walldius, G., Jungner, I., AASTVEIT, A. H., Holme, I., Furberg, C. D., & Sniderman, A. D. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.254 · Cited by 287

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease

Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J., Trevisan, M., & Grundy, S. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.032 · Cited by 277

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262

Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal

Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241

Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes

Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J. P., Trevisan, M., & Grundy, S. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1916 · Cited by 237

Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes

Jiang, R., Schulze, M. B., Li, T., Rifai, N., Stampfer, M. J., Rimm, E. B., & Hu, F. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1991 · Cited by 234

Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and A po B in patients undergoing primary prevention of cardiovascular disease: A triple‐blind, 6‐month follow‐up, placebo‐controlled, randomized trial

Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., García‐Almagro, F. J., Avilés-Plaza, F. V., Parra, S., Yáñez-Gascón, M. J., Ruiz‐Ros, J. A., García‐Conesa, M., Tomás-Barberán, F. A., et al. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100673 · Cited by 211

Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype

Twickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation · doi:10.1161/01.cir.0000125278.58527.f3 · Cited by 201

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

Backes, J., Anzalone, D., Hilleman, D., & Catini, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0286-4 · Cited by 195

Association Between Metabolic Syndrome and Liver Histology Among Children With Nonalcoholic Fatty Liver Disease

Patton, H. M., Yates, K. P., Ünalp–Arida, A., Behling, C. A., Huang, T. T. ‐., Rosenthal, P. J., Sanyal, A. J., Schwimmer, J. B., & Lavine, J. E. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.152 · Cited by 185

New loci and coding variants confer risk for age-related macular degeneration in East Asians

Cheng, C., Yamashiro, K., Chen, L. J., Ahn, J., Huang, L., Huang, L., Cheung, C. M. G., Miyake, M., Cackett, P., Yeo, I. Y. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7063 · Cited by 186

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157

Incident Cardiovascular Disease Events in Metabolically Benign Obese Individuals

Ogorodnikova, A. D., Kim, M., McGinn, A. P., Muntner, P., Khan, U. I., & Wildman, R. P. (2011) · Obesity · doi:10.1038/oby.2011.243 · Cited by 146

Ezetimibe: cholesterol lowering and beyond

Bays, H. E., Neff, D., Tomassini, J. E., & Tershakovec, A. M. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.4.447 · Cited by 147

Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature

Lathe, R., Tsitrina, A. A., & Kotelevtsev, Y. V. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-36 · Cited by 141

Usefulness of Childhood Non–High Density Lipoprotein Cholesterol Levels Versus Other Lipoprotein Measures in Predicting Adult Subclinical Atherosclerosis: The Bogalusa Heart Study

Frontini, M., Srinivasan, S. R., Xu, J.-H., Tang, R., Bond, M. G., & Berenson, G. S. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1472 · Cited by 136

Effects of Periodontal Therapy on Systemic Markers of Inflammation in Patients With Metabolic Syndrome: A Controlled Clinical Trial

López, N., Quintero, A., Casanova, P. A., Ibieta, C. I., Bælum, V., & López, R. (2011) · Journal of Periodontology · doi:10.1902/jop.2011.110227 · Cited by 136

Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 134

Separating extracellular vesicles and lipoproteins via acoustofluidics

Wu, M., Chen, C., Wang, Z., Bachman, H., Ouyang, Y., Huang, P., Sadovsky, Y., & Huang, T. J. (2019) · Lab on a Chip · doi:10.1039/c8lc01134f · Cited by 129

Patients' Preferred Terms for Describing Their Excess Weight: Discussing Obesity in Clinical Practice

Volger, S., Vetter, M. L., Dougherty, M., Panigrahi, E., Egner, R., Webb, V., Thomas, J. G., Sarwer, D. B., & Wadden, T. A. (2011) · Obesity · doi:10.1038/oby.2011.217 · Cited by 122

Stroke mortality and the apoB/apoA‐I ratio: results of the AMORIS prospective study

Walldius, G., AASTVEIT, A. H., & Jungner, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01610.x · Cited by 122

Apolipoproteins as markers and managers of coronary risk

Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II

Ballantyne, C. M., Bertolami, M. C., García, H. R. H., Nul, D. R., Stein, E. A., Théroux, P., Weiss, R., Cain, V. A., & Raichlen, J. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.12.013 · Cited by 112

Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-year Chinese Multi-Provincial Cohort Study (CMCS)

Ren, J., Grundy, S. M., Liu, J., Wang, W., Wang, M., Sun, J., Liu, J., Li, Y., Wu, Z., & Zhao, D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.020 · Cited by 111

Obesity and body fat classification in the metabolic syndrome: Impact on cardiometabolic risk metabotype

Phillips, C. M., Tierney, A. C., Pérez‐Martínez, P., Defoort, C., Blaak, E. E., Gjelstad, I. M. F., López‐Miranda, J., Kieć-Klimczak, M., Malczewska-Malec, M., Drevon, C. A., et al. (2013) · Obesity · doi:10.1002/oby.20263 · Cited by 110

Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS)

Holme, I., Aastveit, A. H., Jungner, I., & Walldius, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01925.x · Cited by 106

Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients

Ballantyne, C. M., Raichlen, J. S., & Cain, V. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.052 · Cited by 102

A high intake of dietary fiber influences C-reactive protein and fibrinogen, but not glucose and lipid metabolism, in mildly hypercholesterolemic subjects

Johansson‐Persson, A., Ulmius, M., Cloetens, L., Karhu, T., Herzig, K., & Önning, G. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0496-8 · Cited by 102

Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

Buse, J. B., Rubin, C. J., Frederich, R. C., Viraswami-Appanna, K., Lin, K.-C., Montoro, R. J., Shockey, G., & Davidson, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.08.005 · Cited by 99

Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia

Blais, P., Lin, M. F., Kramer, J. R., El‐Serag, H. B., & Kanwal, F. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4000-6 · Cited by 93

Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia

Skulas-Ray, A. C., West, S. G., Davidson, M. H., & Kris-Etherton, P. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1237 · Cited by 91

Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective

Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M. J., García‐Almagro, F. J., Ruiz‐Ros, J. A., Tomás-Barberán, F. A., García‐Conesa, M., & Espı́n, J. C. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12150 · Cited by 88

Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy

Walldius, G., & Jungner, I. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi077 · Cited by 88

Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated?

Davidson, M. H. (2009) · Clinical Cardiology · doi:10.1002/clc.20559 · Cited by 87

Long‐term Successful Weight Loss Improves Vascular Endothelial Function in Severely Obese Individuals

Bigornia, S., Mott, M. M., Hess, D. T., Apovian, C. M., McDonnell, M. E., Duess, M., Kluge, M. A., Fiscale, A. J., Vita, J. A., & Gokce, N. (2010) · Obesity · doi:10.1038/oby.2009.482 · Cited by 80

Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes

Peters, A. L. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.3 · Cited by 78

Prevalence of the metabolic syndrome in Peruvian Andean hispanics: The PREVENCION study

Medina‐Lezama, J., Zea-Díaz, H., Morey‐Vargas, O. L., Bolaños-Salazar, J. F., Muñoz-Atahualpa, E., Dowall, M. P. M., Corrales‐Medina, F. F., Valdivia-Ascuña, Z., Cuba-Bustinza, C., Diaz, S. P., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.04.004 · Cited by 76

Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease.

Olofsson, S., Wiklund, O., & Borén, J. (2007) · PubMed Central · Cited by 73

Exposure to improved nutrition from conception to age 2 years and adult cardiometabolic disease risk: a modelling study

Ford, N. D., Behrman, J. R., Hoddinott, J. F., Maluccio, J. A., Martorell, R., Ramírez‐Zea, M., & Stein, A. D. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30231-6 · Cited by 71

LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker

Aggarwal, D. J., Kathariya, G., & Verma, P. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.07.013 · Cited by 72

Association of Renal Resistive Index With Target Organ Damage in Essential Hypertension

Doi, Y., Iwashima, Y., Yoshihara, F., Kamide, K., Takata, H., Fujii, T., Kubota, Y., Nakamura, S., Horio, T., & Kawano, Y. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.113 · Cited by 68

Daily Supplementation with (n-3) PUFAs, Oleic Acid, Folic Acid, and Vitamins B-6 and E Increases Pain-Free Walking Distance and Improves Risk Factors in Men with Peripheral Vascular Disease

Carrero, J. J., López‐Huertas, E., Salmerón, L. M., Baró, L., & Ros, E. (2005) · Journal of Nutrition · doi:10.1093/jn/135.6.1393 · Cited by 67

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics

Lee, R. G., Crosby, J. R., Baker, B. F., Graham, M. J., & Crooke, R. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9495-7 · Cited by 66

Therapeutic approaches to drug targets in hyperlipidemia

Mahamuni, S. P., Khose, R. D., Menaa, F., & Badole, S. L. (2012) · Biomedicine · doi:10.1016/j.biomed.2012.08.002 · Cited by 66

Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm

Sniderman, A. D. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137220.39031.3b · Cited by 62

Eicosanoids and renal damage in cardiometabolic syndrome

Imig, J. D. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.165 · Cited by 59

Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients

Wägner, A. M., Pérez, A., Zapico, E., & Ordóñez‐Llanos, J. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2048 · Cited by 58

Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B

Stein, E. A., Sniderman, A. D., & Laskarzewski, P. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.006 · Cited by 58

Intake of Fish Oil, Oleic Acid, Folic Acid, and Vitamins B-6 and E for 1 Year Decreases Plasma C-Reactive Protein and Reduces Coronary Heart Disease Risk Factors in Male Patients in a Cardiac Rehabilitation Program

Carrero, J. J., Fonollá, J., Marti, J. L., Jiménez, J., Bozá, J., & López‐Huertas, E. (2007) · Journal of Nutrition · doi:10.1093/jn/137.2.384 · Cited by 56

A Review of Lipid Management in Primary and Secondary Prevention

Dembowski, E., & Davidson, M. H. (2009) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318192754e · Cited by 53

Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk

Sharma, R. K. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5684 · Cited by 50

Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering

Pikuleva, I. A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.11.1403 · Cited by 49

Molecular actions of hypocholesterolaemic compounds from edible mushrooms

Gil‐Ramírez, A., Morales, D., & Soler‐Rivas, C. (2017) · Food & Function · doi:10.1039/c7fo00835j · Cited by 48

IMPACT OF ANTIOXIDANTS FROM DRUMSTICK LEAVES ON THE LIPID PROFILE OF HYPERLIPIDEMICS

Nambiar, V. S., Guin, P., Parnami, S., & Daniel, M. (2010) · Cited by 48

Diabetes Nutrition and Complications Trial

Cruz, A. F., & Calle‐Pascual, A. L. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.984 · Cited by 48

Present and future therapeutic strategies in non-alcoholic fatty liver disease

Calamita, G., & Portincasa, P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1231 · Cited by 47

Correlation of Non–High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)

Grundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.018 · Cited by 47

Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials

Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45

Effect of leisure time physical activity on blood lipid levels: the ATTICA study

Panagiotakos, D. B., Pitsavos, C. E., Chrysohoou, C. A., Skoumas, J., Zeimbekis, A., Papaioannou, I., & Stefanadis, C. (2003) · Coronary Artery Disease · doi:10.1097/00019501-200312000-00003 · Cited by 45

Metabolic Syndrome: Therapeutic Considerations

Grundy, S. M. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_3 · Cited by 44

Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease

Okazaki, M., Usui, S., Fukui, A., Kubota, I., & Tomoike, H. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.070094 · Cited by 44

Prevention of Cardiovascular Ischemic Events

Genest, J. J., & Pedersen, T. R. (2003) · Circulation · doi:10.1161/01.cir.0000067881.26274.bd · Cited by 43

Interruption of Autophagosome Formation in Cardiovascular Disease, an Evidence for Protective Response of Autophagy

Khalil, H., Maksoud, A. I. A. E., Alian, A., El-Hamady, W. A., Daif, A., Awad, A. M., & Guirgis, A. A. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1635619 · Cited by 42

MRI Measured Epicardial Adipose Tissue Thickness at the Right AV Groove Differentiates Inflammatory Status in Obese Men With Metabolic Syndrome

Liang, K., Tsai, I., Lee, W., Lee, I., Lee, W., Lin, S., Wan, C., Fu, C., Ting, C.-T., & Sheu, W. H. (2011) · Obesity · doi:10.1038/oby.2011.155 · Cited by 41

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Kumar, A. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5686 · Cited by 41

Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia

Færgeman, O., Hill, L., Windler, E., Wiklund, O., Asmar, R., Duffield, E. L., & Sosef, F. (2008) · Cardiology · doi:10.1159/000127442 · Cited by 40

Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome

Sardu, C., Santamaria, M., Funaro, S., Sacra, C., Barbieri, M., Paolisso, P., Marfella, R., Paolisso, G., & Rizzo, M. R. (2017) · Medicine · doi:10.1097/md.0000000000006558 · Cited by 39

May subclinical arterial disease help to better detect and treat high-risk asymptomatic individuals?

Simon, A. C., & Levenson, J. A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000184407.20257.58 · Cited by 39

Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial

for the CASE-J Trial Group, Nakao, K., Hirata, M., Oba, K., Yasuno, S., Ueshima, K., Fujimoto, A., Ogihara, T., & Saruta, T. (2010) · Hypertension Research · doi:10.1038/hr.2010.38 · Cited by 37

Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals

Rallidis, L. S., Pitsavos, C. E., Panagiotakos, D. B., Sinos, L., Stefanadis, C., & Kremastinos, D. T. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.09.022 · Cited by 36

Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention

Ascaso, J. F., ndez-Cruz, A. F., Santos, P. G. L., Hernández‐Mijares, A., Mangas, A., n, J. M., Pallardo, L. F., Pedro‐Botet, J., Pérez‐Jiménez, F., a, G. P., et al. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404050-00003 · Cited by 36

Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice

Song, G., Tian, H., Qin, S., Sun, X., Yao, S., Zong, C., Luo, Y., Liu, J., Yu, Y., Sang, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.043 · Cited by 35

Association of kidney function-related dietary pattern, weight status, and cardiovascular risk factors with severity of impaired kidney function in middle-aged and older adults with chronic kidney disease: a cross-sectional population study

Kurniawan, A. L., Hsu, C., Rau, H.-H., Lin, L.-Y., & Chao, J. C.-J. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0452-4 · Cited by 35

Association of Simvastatin and Hyperlipidemia With Periodontal Status and Bone Metabolism Markers

Magán‐Fernández, A., Ramírez, L. P., Tomás, J., Marfil‐Álvarez, R., Rizzo, M., Bravo, M., & Mesa, F. (2014) · Journal of Periodontology · doi:10.1902/jop.2014.130652 · Cited by 34

Efficacy and safety of mipomersen sodium (Kynamro)

Hovingh, K., Besseling, J., & Kastelein, J. J. P. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793670 · Cited by 33

Carotid artery thickness in children and young adults with end stage renal disease

Poyrazoğlu, H. M., Düşünsel, R., Yıkılmaz, A., Narın, N., Anarat, R., Gündüz, Z., Çoşkun, A., Baykan, A., & Ozturk, A. B. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0268-2 · Cited by 33

Increased serum lipids are associated with higher CD4 lymphocyte count in HIV‐infected women

Floris-Moore, M., Howard, A., Lo, Y., Arnsten, J. H., Santoro, N. F., & Schoenbaum, E. E. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00401.x · Cited by 32

Increased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery Disease

Brunzell, J. D. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000156537.78366.1d · Cited by 32

Blood stasis syndrome of coronary heart disease: A perspective of modern medicine

Gui, Y., & Wang, J. (2013) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-013-1332-3 · Cited by 31

CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention

Gohlke, H., Winter, M., Karoff, M., & Held, K. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000244581.30421.69 · Cited by 31

Single‐center retrospective study of long‐term use of low‐dose acitretin (Soriatane®) for psoriasis

Lee, E., & Koo, J. Y. M. (2004) · Journal of Dermatological Treatment · doi:10.1080/095466303100184473 · Cited by 31

Effect of different LDL‐apheresis methods on parameters involved in atherosclerosis

Hershcovici, T., Schechner, V., ORLIN, J. B., Harell, D., & Beigel, Y. (2004) · Journal of Clinical Apheresis · doi:10.1002/jca.20006 · Cited by 30

Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice

Mühlfeld, A., Spencer, M. W., Hudkins, K. L., Kirk, E. A., LeBoeuf, R. C., & Alpers, C. E. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00854.x · Cited by 30

Effects of the Addition of T'ai Chi to a Dietary Weight Loss Program on Lipoprotein Atherogenicity in Obese Older Women

Beebe, N., Magnanti, S., Katkowski, L., Benson, M. C., Xu, F., Delmonico, M. J., & Lofgren, I. E. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.0531 · Cited by 29

Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

Dayspring, T. D., Qu, Y., & Keech, C. A. (2006) · Metabolism · doi:10.1016/j.metabol.2006.03.005 · Cited by 29

Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome

Cottrell, D. A., Marshall, B. J., & Falko, J. M. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200307000-00010 · Cited by 29

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease

Le, N., Tomassini, J. E., Tershakovec, A. M., Neff, D., & Wilson, P. W. F. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001675 · Cited by 28

Food prices and blood cholesterol

Rahkovsky, I. M., & Gregory, C. (2012) · Economics & Human Biology · doi:10.1016/j.ehb.2012.01.004 · Cited by 27

Prevention of heart failure in the elderly: when, where and how to begin?

Jugdutt, B. I. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9299-x · Cited by 26

Evaluation of non-HDL-c and total cholesterol: HDL-c Ratio as Cumulative Marker of Cardiovascular Risk in Diabetes Mellitus

Aryal, M. S., Poudel, A., Satyal, B., Gyawali, P., Pokheral, B. R., Raut, B., Adhikari, R., & Koju, R. (2012) · Kathmandu University Medical Journal · doi:10.3126/kumj.v8i4.6239 · Cited by 26

LDL、非-HDL及apoB是降脂治疗的靶标

余国膺 (2003) · South China Journal of Cardiovascular Diseases

Research digest: new insights into established risk pathways

Preiss, D., & Sattar, N. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30091-9

The role of non-LDL:non-HDL particles in atherosclerosis

Segrest, J. P. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0096-0 · Cited by 26

Low-density lipoprotein, non high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation

Grundy, S. M., Lipoprotein, L.-D., Lipoprotein, N.-H.-D., & As, A. B. (2015)

An increased number of very-low-density lipoprotein particles is strongly associated with coronary heart disease in Japanese men, independently of intermediate-density lipoprotein or low-density lipoprotein

Koba, S., Hirano, T., Sakaue, T., Takeuchi, H. T., Adachi, M., & Katagiri, T. (2002) · Coronary Artery Disease · doi:10.1097/00019501-200208000-00002 · Cited by 23